Rineterkib

DB17560InvestigationalSmall molecule

Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in...

Mechanism: Pharmacologically active on Extracellular signal-regulated kinase (ERK)
Curator reviewed
Formula / weight: C₂₆H₂₇BrF₃N₅O₂ · 578.434 g/mol (avg)
Code names: LTT 462

Resolves to

Compound

UNII15KFN616FKCAS1715025-32-3ChEMBLCHEMBL3909517

Structure

InChIKeyYFCIFWOJYYFDQP-PTWZRHHISA-NSMILESCNC[C@@H](NC(=O)C1=CC=C(C=C1F)C1=NC(=CN=C1N)[C@H]1CC[C@H](O)[C@@H](F)C1)C1=CC(F)=CC(Br)=C1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Rineterkib, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account